Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,988 GBX | -0.32% | +9.52% | +13.09% |
03:26pm | ASTRAZENECA : DZ Bank sticks Neutral | ZD |
03:11pm | ASTRAZENECA : UBS keeps a Sell rating | ZD |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The firm trades with high earnings multiples: 21.92 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.09% | 233B | B+ | ||
+25.73% | 653B | C+ | ||
+27.00% | 556B | B | ||
-6.81% | 354B | C+ | ||
+20.30% | 331B | B- | ||
+2.73% | 296B | C+ | ||
+5.46% | 201B | B- | ||
-9.61% | 193B | A+ | ||
-6.10% | 144B | C+ | ||
-11.58% | 143B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC